- Home
- PIII vs PHIO Comparison
PIII vs PHIO Comparison
Compare PIII & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PIII | PHIO |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 12.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PIII | PHIO |
|---|---|---|
| Price | $1.65 | $1.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $16.25 | $10.67 |
| AVG Volume (30 Days) | 19.8K | ★ 363.3K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,444,952,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.75 | $0.97 |
| 52 Week High | $12.45 | $4.19 |
Technical Indicators
Market Signals| Indicator | PIII | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 20.17 | 37.55 |
| Support Level | $2.54 | $1.09 |
| Resistance Level | $2.63 | $1.10 |
| Average True Range (ATR) | 0.40 | 0.06 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 13.86 | 6.82 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.